Core Viewpoint - Kingworld Medicines Group expects a significant decline in profit for the first half of 2025, projecting a year-on-year decrease of approximately 70% to 75%, resulting in a loss of around RMB 4.5 million attributable to shareholders [1] Summary by Category Financial Performance - The company anticipates a profit drop of about 70% to 75% for the first half of 2025, translating to a loss of approximately RMB 4.5 million [1] Business Operations - The decline in performance is primarily attributed to a decrease in gross profit margins of 50% to 55% in the distribution of imported pharmaceutical and health products in China, driven by a slowdown in market demand [1]

Core Viewpoint - Kingworld Medicines Group (01110) expects a significant decline in profit for the first half of 2025, projecting a year-on-year decrease of approximately 70% to 75% compared to a profit of 45.6 million yuan in the first half of 2024 [1] Financial Performance - The company anticipates a loss attributable to shareholders of approximately 4.5 million yuan for the first half of 2025, while projecting a profit attributable to shareholders of about 30.7 million yuan for the first half of 2024 [1] Business Operations - The board attributes the decrease in profit primarily to a reduction in gross profit of approximately 50% to 55% from its Chinese distribution business for imported pharmaceutical and health products, which is due to a slowdown in market demand for these products [1] - This decline in gross profit is partially offset by an increase in gross profit of about 10% to 15% from Shenzhen Dongdixin Technology Co., Ltd [1]

Core Viewpoint - The company, JinHuo Pharmaceutical Group, anticipates a significant decline in profits for the first half of 2025, projecting a decrease of approximately 70% to 75% compared to the same period in 2024, where profits were reported at 45.6 million yuan [1] Financial Performance - For the first half of 2024, the company reported a profit attributable to owners of approximately 30.7 million yuan [1] - The company expects a loss attributable to owners of about 4.5 million yuan for the first half of 2025 [1] Business Operations - The board attributes the profit decline primarily to a reduction in gross margins of about 50% to 55% in the Chinese distribution business for imported pharmaceutical and health products, driven by a slowdown in market demand [1] - This decline in gross margin is partially offset by an increase in gross margin of approximately 10% to 15% from Shenzhen Dongdixin Technology Co., Ltd [1]